Response Pharmaceuticals, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$4M
Investors
51
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Response Pharmaceuticals, Inc. is a Delaware corporation that first filed a Form D on March 1, 2022 and most recently amended it on June 28, 2024 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers debt. Response Pharmaceuticals, Inc. reported $3,898,385 sold from 51 investors of a $5,000,000 total offering as of the Form D filed June 28, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Collage Venture Partners, LLC (CRD 316063), associated with None; Stonehaven, LLC (CRD 118913), associated with None as recipients of sales compensation soliciting in AL, CA, NJ, NY, PA. Sales commissions are reported as $0 and finders' fees as $286,406. Form D allows these to be estimates. The issuer's address of record is 1104 West Broad Street #1064, Falls Church, VA 22046.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jun 28, 2024
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
2
lapsed
Latest event New filer · Jun 28, 2024
SEC.govInvestor
- 1 filing event with values and deltas, latest 2024-06-28, and alerts on the next one
- 2 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2024-06-28: 2 related persons added and 1 removed against the filing of 2022-12-05; 3 now listed. The names are in the Terminal feed.
Eric Keller
Executive Officer, Director · Falls Church, VA
Donald Olds
Director · Falls Church, VA
Michael Berendt
Director · Falls Church, VA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Collage Venture Partners, LLCCRD 316063 on BrokerCheck
Associated broker-dealer: None · Miami Beach, FL · Soliciting in AL, CA, NJ, NY, PA
Stonehaven, LLCCRD 118913 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Questions About Response Pharmaceuticals, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Response Pharmaceuticals, Inc.?
Response Pharmaceuticals, Inc. is a Delaware corporation that filed a Form D with the SEC on June 28, 2024 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of debt.
Is Response Pharmaceuticals, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Response Pharmaceuticals, Inc. filed a Form D with the SEC on June 28, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $3,898,385 sold to 51 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Response Pharmaceuticals, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Response Pharmaceuticals, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Response Pharmaceuticals, Inc. raised?
Response Pharmaceuticals, Inc. reported $3,898,385 sold from 51 investors of a $5,000,000 total offering as of the Form D filed June 28, 2024.
Who can invest in Response Pharmaceuticals, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Response Pharmaceuticals, Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Response Pharmaceuticals, Inc. and how are they paid?
The Form D names Collage Venture Partners, LLC (CRD 316063), associated with None; Stonehaven, LLC (CRD 118913), associated with None as recipients of sales compensation soliciting in AL, CA, NJ, NY, PA. Sales commissions are reported as $0 and finders' fees as $286,406. Form D allows these to be estimates.
Who is behind Response Pharmaceuticals, Inc.?
The Form D lists 3 related persons: Eric Keller, executive officer, director; Donald Olds, director; Michael Berendt, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Response Pharmaceuticals, Inc. located?
The issuer's address on its SEC filings is 1104 West Broad Street #1064, Falls Church, VA 22046. Its phone number of record is 703-624-2024. It is organized under the laws of Delaware.
How long is the Response Pharmaceuticals, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
What is Response Pharmaceuticals, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
